Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2318-2325

  Sugishita, Yoshiyuki ^a   Kammori, Makoto ^a   Yamada, Osamu ^b   Yamazaki, Kazuko ^a   Ito, Ken Ichi ^c   Fukumori, Tatsuya ^a   Yoshikawa, Kei Ichi ^a   Yamada, Tetsu ^a  

^a Kanaji Thyroid Hospital   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADENOMA; ADULT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOCYTOMA; PROTEIN EXPRESSION; TELOMERE; TELOMERE SHORTENING; THYROID FOLLICULAR CARCINOMA; THYROIDECTOMY; ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; TELOMERE HOMEOSTASIS; THYROID NEOPLASMS;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADENOMA, OXYPHILIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TELOMERASE; TELOMERE HOMEOSTASIS; THYROID NEOPLASMS;

EID: 84902150863     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3552-6     Document Type: Article

References (52)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer. 1998;83:2638-48.
2. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G, Niederle B. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer. 2004;11:131-9.
3. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine. 1977;56:171-96.
4. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103:2269-73.
5. Yokozawa T, Miyauchi A, Kuma K, Sugawara M. Accurate and simple method of diagnosing thyroid nodules the modified technique of ultrasound-guided fine needle aspiration biopsy. Thyroid. 1995;5:141-5.
6. DeLellis RA, Lloyd RV, Heitz PV, Eng C, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of endocrine organs. vol 49. Lyon: IRAC; 2004. p.134.
7. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26:1016-23.
8. Dettmer M, Vogetseder A, Durso MB, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab. 2013;98:E1-7.
9. Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013;98:E962-72.
10. Kushchayeva Y, Duh QY, Kebebew E, D'Avanzo A, Clark OH. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg. 2008;195:457-62.
11. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118:1131-8.
12. Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg. 2004;28:1266-70.
13. Yutan E, Clark OH. Hürthle cell carcinoma. Curr Treat Options Oncol. 2001;2:331-5.
14. Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol. 1986;10:246-55.
15. Grant CS, Hay ID, Ryan JJ, Bergstralh EJ, Rainwater LM, Goellner JR. Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors. World J Surg. 1990;14:283-9.
16. Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K. Hürthle cell tumor of the thyroid: analysis of 188 cases. World J Surg. 2001;25:1160-3.
17. Haigh PI, Urbach DR. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery. 2005;138:1152-8.
18. Ito Y, Hirokawa M, Higashiyama T, et al. Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg. 2007;31:1417-24.
19. Sugino K, Kameyama K, Ito K, et al. Does Hürthle cell carcinoma of the thyroid have a poorer prognosis than ordinary follicular thyroid carcinoma? Ann Surg Oncol. 2013;20:2944-50.
20. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-73.
21. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458-60.
22. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27:339-44.
23. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 1995;5:249-55.
24. de Lange T. Telomeres and senescence: ending the debate. Science. 1998;279:334-55.
25. DePinho RA. The age of cancer. Nature. 2000;408:248-54.
26. Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009;1792:317-23.
27. Wyatt HD, West SC, Beattie TL. InTERTpreting telomerase structure and function. Nucleic Acids Res. 2010;38:5609-22.
28. Kammori M, Nakamura K, Hashimoto M, Ogawa T, Kaminishi M, Takubo K. Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization. Int J Oncol. 2003;22:985-91.
29. Furugori E, Hirayama R, Nakamura K, Kammori M, Esaki Y, Takubo K. Telomere shortening in gastric carcinoma with aging despite telomerase activation. J Cancer Res Clin Oncol. 2000;126:481-5.
30. Nakamura K, Furugori E, Esaki Y, et al. Correlation of telomere lengths in normal and cancers tissue in the large bowel. Cancer Lett. 2000;158:179-84.
31. Kammori M, Takubo K, Nakamura K, et al. Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett. 2000;159:175-81.
32. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet. 2002;32:280-4.
33. Meeker AK, Gage WR, Hicks JL, et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol. 2002;160:1259-68.
34. Sugishita Y, Kammori M, Yamada O, et al. Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening. Int J Oncol. 2013;42:1589-96.
35. Kammori M, Kanauchi H, Nakamura K, et al. Demonstration of human telomerase reverse transcriptase in human colorectal carcinomas by in situ hybridization. Int J Oncol. 2002;20:15-21.
36. Aida J, Izumiyama-Shimomura N, Nakamura K, et al. Telomere length variations in 6 mucosal cell types of gastric tissue observed using a novel quantitative fluorescence in situ hybridization method. Hum Pathol. 2007;38:1192-200.
37. Kammori M, Izumiyama N, Nakamura K, et al. Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology 2006;71:430-6.
38. Kawauchi K, Ihjima K, Yamada O. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol. 2005;174:5261-69.
39. Kurabayashi R, Takubo K, Aida J, et al. Luminal and cancer cells in the breast show more rapid telomere shortening than myoepithelial cells and fibroblasts. Hum Pathol. 2008;39:1647-55.
40. Lo CY, Chan WF, Lam KY, Wan KY. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg. 2005;242:708-15.
41. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007;14:730-8.
42. Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M, Niederle B. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg. 2009;249:1023-31.
43. Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK. Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res. 2007;13:7037-43.
44. Donaldson L, Fordyce C, Gilliland F, et al. Association between outcome and telomere DNA content in prostate cancer. J Urol. 1999;162:1788-92.
45. Frías C, García-Aranda C, De Juan C, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer. 2008;60:416-25.
46. Wang Y, Meeker AK, Kowalski J, et al. Telomere length is related to alternative splice patterns of telomerase in thyroid tumors. Am J Pathol. 2011;179:1415-24.
47. Umbricht CB, Conrad GT, Clark DP, et al. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. Clin Cancer Res. 2004;10:5762-8.
48. Wang Y, Kowalski J, Tsai HL, et al. Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid. 2008;18:1055-63.
49. Thomas GA, Williams D, Williams ED. The clonal origin of thyroid nodules and adenomas. Am J Pathol. 1989;134:141-7.
50. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88:2745-52.
51. Sarquis MS, Weber F, Shen L, et al. High frequency of loss of heterozygosity in imprinted, compared with non imprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas. J Clin Endocrinol Metab. 2006;91:262-9.
52. Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hürthle cell lesions of the thyroid gland. Surg Gynecol Obstet. 1974;139:555-60.